Globotriaosylsphingosine (lyso-Gb3) might not be a reliable marker for monitoring the long-term therapeutic outcomes of enzyme replacement therapy for late-onset Fabry patients with the Chinese hotspot mutation (IVS4+919G>A)

BACKGROUND: In Taiwan, DNA-based newborn screening showed a surprisingly high incidence (1/875 in males and 1/399 in females) of a cardiac Fabry mutation (IVS4 + 919G > A). However, the natural course, long-term treatment outcomes and suitable biomarkers for monitoring the therapeutic outcomes of...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hao-Chuan, Lin, Hsiang-Yu, Yang, Chia-Feng, Liao, Hsuan-Chieh, Hsu, Ting-Rong, Lo, Chiao-Wei, Chang, Fu-Pang, Huang, Chun-Kai, Lu, Yung-Hsiu, Lin, Shuan-Pei, Yu, Wen-Chung, Niu, Dau-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223723/
https://www.ncbi.nlm.nih.gov/pubmed/25047006
http://dx.doi.org/10.1186/s13023-014-0111-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4223723/
https://www.ncbi.nlm.nih.gov/pubmed/25047006
http://dx.doi.org/10.1186/s13023-014-0111-y

Ejemplares similares